Immunocore Holdings plc 10-Q

Item 5. Other Information Insider Trading Arrangements During our last fiscal quarter, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities as set forth in the table below. Type of Trading Arrangement Name and Position Action Adoption/ Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Ordinary Shares to be Sold (3) Expiration Date David Berman EVP, Research and Development Termination February 28, 2026 X 471,790 November 20, 2026 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents ordinary shares in the form of American Depositary Shares. 29 Table of Contents Item 6. Exhibits Exhibit Number Incorporation by Reference Description Schedule / Form File Number Exhibit Filing Date 3.1 Articles of Association of Immunocore Holdings plc 10-Q 001-39992 3.1 August 8, 2024 31.1* Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1 ** Certification by the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS* Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). 101.SCH* Inline XBRL Taxonomy Extension with Embedded Linkbase Schema Documents. 104* Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). * Filed herewith. ** This certification is deemed furnished, not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act. 30 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOCORE HOLDINGS PLC Date: May 6, 2026 By: /s/ Bahija Jallal Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer (On Behalf of the Registrant and as Principal Executive Officer) Date: May 6, 2026 By: /s/ Travis Coy Name: Travis Coy Title: Chief Financial Officer ( Principal Financial Officer) 31